Back to Directory
Last Updated: 09/06/2026
Pulmocide
London
Founded 2007
Inhaled antifungal therapies for serious respiratory fungal infections
Pulmocide is a late-stage biopharmaceutical company developing inhaled medicines for life-threatening respiratory fungal infections.
Its lead compound opelconazole is a triazole antifungal designed for inhaled delivery to maximise pulmonary drug concentration while minimising systemic exposure and drug interactions.
The compound is in a multinational Phase 3 trial for invasive pulmonary aspergillosis in patients failing standard antifungal therapy.
Additional indications include aspergilloma, allergic bronchopulmonary aspergillosis, and lung transplant prophylaxis.